JP7798805B2 - 抗ＴＧＦβ抗体及びその治療的使用 - Google Patents

抗ＴＧＦβ抗体及びその治療的使用

Info

Publication number
JP7798805B2
JP7798805B2 JP2022576392A JP2022576392A JP7798805B2 JP 7798805 B2 JP7798805 B2 JP 7798805B2 JP 2022576392 A JP2022576392 A JP 2022576392A JP 2022576392 A JP2022576392 A JP 2022576392A JP 7798805 B2 JP7798805 B2 JP 7798805B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022576392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530663A5 (https=
JP2023530663A (ja
JPWO2021252455A5 (https=
Inventor
リサ マリー ベルジェロン
ゲイリー エフ バマート
ヘンリー ルイス カンポス
サンドラ アン マリー ライトル
キャサリン ジェイ ストリーツェル
Original Assignee
ゾエティス・サービシーズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾエティス・サービシーズ・エルエルシー filed Critical ゾエティス・サービシーズ・エルエルシー
Publication of JP2023530663A publication Critical patent/JP2023530663A/ja
Publication of JP2023530663A5 publication Critical patent/JP2023530663A5/ja
Publication of JPWO2021252455A5 publication Critical patent/JPWO2021252455A5/ja
Application granted granted Critical
Publication of JP7798805B2 publication Critical patent/JP7798805B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022576392A 2020-06-08 2021-06-08 抗ＴＧＦβ抗体及びその治療的使用 Active JP7798805B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036092P 2020-06-08 2020-06-08
US63/036,092 2020-06-08
PCT/US2021/036347 WO2021252455A1 (en) 2020-06-08 2021-06-08 ANTI-TGFβ ANTIBODIES AND THERAPEUTIC USES THEREOF

Publications (4)

Publication Number Publication Date
JP2023530663A JP2023530663A (ja) 2023-07-19
JP2023530663A5 JP2023530663A5 (https=) 2024-12-16
JPWO2021252455A5 JPWO2021252455A5 (https=) 2024-12-16
JP7798805B2 true JP7798805B2 (ja) 2026-01-14

Family

ID=76708478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576392A Active JP7798805B2 (ja) 2020-06-08 2021-06-08 抗ＴＧＦβ抗体及びその治療的使用

Country Status (13)

Country Link
US (1) US20220119513A1 (https=)
EP (1) EP4161654A1 (https=)
JP (1) JP7798805B2 (https=)
KR (1) KR20230022974A (https=)
CN (1) CN115803342A (https=)
AU (1) AU2021287868A1 (https=)
BR (1) BR112022024195A2 (https=)
CA (1) CA3186707A1 (https=)
CO (1) CO2023000068A2 (https=)
DK (1) DK202370008A1 (https=)
MX (1) MX2022015609A (https=)
PH (1) PH12022500030A1 (https=)
WO (1) WO2021252455A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4178977A1 (en) 2020-07-10 2023-05-17 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
WO2023049917A1 (en) * 2021-09-27 2023-03-30 Zoetis Services Llc ANTI- TGFβ1,2,3 ANTIBODIES AND THERAPEUTIC USES THEREOF
WO2024145280A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
EP4642795A2 (en) 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
CN117106082B (zh) * 2023-09-15 2024-10-29 成都蓉生药业有限责任公司 一种抗TGFβ的人源化纳米抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
JP4805461B2 (ja) 1999-03-18 2011-11-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 血小板接着の阻止用タンパク質
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6790639B2 (en) 2000-02-29 2004-09-14 Pfizer Inc. Mammalian osteoregulins
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
EP1485126A4 (en) 2001-12-21 2007-03-21 Idexx Lab Inc DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE
JP2009521496A (ja) * 2005-12-23 2009-06-04 イーライ リリー アンド カンパニー ＴＧＦ−β結合組成物
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
PT2971048T (pt) * 2013-03-11 2019-02-06 Genzyme Corp Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TW202506185A (zh) * 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
US20200392219A1 (en) * 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
WO2020095113A1 (en) * 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES，2017年05月05日，VOL:18, NR:5，PAGE(S):985(1-11)，http://dx.doi.org/10.3390/ijms18050985
J Vet Intern Med，2014年，Vol.28, No.6，p.1666-1675
PLOS ONE，2016年05月17日，PAGE(S):0155534(1-17)，https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871338/pdf/pone.0155534.pdf
THE LARYNGOSCOPE，2008年03月，VOL:118, NR:3，PAGE(S):546 - 551，http://dx.doi.org/10.1097/MLG.0b013e31815daf6e
UniProtKB/Swiss-Prot [online]，2020年04月22日，Accession No. P27090，entry version 175，https://rest.uniprot.org/unisave/P27090?format=txt&versions=175，［検索日 2025.05.09］
UniProtKB/Swiss-Prot [online]，Accession No. P04202，2020年04月20日，entry version 216，https://rest.uniprot.org/unisave/P04202?format=txt&versions=216，［検索日 2025.05.09］
UniProtKB/Swiss-Prot [online]，Accession No. P17125，2020年02月26日，entry version 165，https://rest.uniprot.org/unisave/P17125?format=txt&versions=165，［検索日 2025.05.09］
UniProtKB/TrEMBL [online]，Accession No. F1PKH0，2020年04月22日，entry version 60，https://rest.uniprot.org/unisave/F1PKH0?format=txt&versions=60，［検索日 2025.05.09］
UniProtKB/TrEMBL [online]，Accession No. Q2PPL2，2020年02月26日，entry version 61，https://rest.uniprot.org/unisave/Q2PPL2?format=txt&versions=61，［検索日 2025.05.09］

Also Published As

Publication number Publication date
MX2022015609A (es) 2023-04-20
DK202370008A1 (en) 2023-01-31
CO2023000068A2 (es) 2023-01-16
WO2021252455A1 (en) 2021-12-16
BR112022024195A2 (pt) 2023-02-07
US20220119513A1 (en) 2022-04-21
CA3186707A1 (en) 2021-12-16
JP2023530663A (ja) 2023-07-19
KR20230022974A (ko) 2023-02-16
PH12022500030A1 (en) 2024-02-26
EP4161654A1 (en) 2023-04-12
CN115803342A (zh) 2023-03-14
AU2021287868A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
JP7798805B2 (ja) 抗ＴＧＦβ抗体及びその治療的使用
JP7746436B2 (ja) 獣医学使用のためのインターロイキン３１モノクローナル抗体
US12552871B2 (en) Nucleic acids encoding humanized anti-NGF antibodies
AU2018201858B2 (en) Caninized anti-ngf antibodies and methods thereof
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
JP7497293B2 (ja) インターロイキン－３１に対するペプチドワクチン
US20220106391A1 (en) Anti-ngf antibodies and methods of use thereof
RU2859871C2 (ru) Антитела анти-TGFβ и их терапевтическое применение
JP2025503707A (ja) ガレクチン－１０抗体
US20230192834A1 (en) Anti- tgfb1,2,3 antibodies and therapeutic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251225

R150 Certificate of patent or registration of utility model

Ref document number: 7798805

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150